Investor Relations

Company Overview

We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.

We are advancing programs in women’s health, including endometriosis-associated pain and egg maturation in assisted reproduction, including in vitro fertilization (IVF), and the prevention of pregnancy.

Over time, we intend to expand our development pipeline to include potential treatments for women's health.

FDA Approved Drugs: ORGOVYX (relugolix 120 mg), MYFEMBREE (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg)

Copyright West LLC. Share price minimum 15 minutes delayed. Market cap from previous market close.

Press Releases
June 1, 2021
Myovant Sciences to Present at Upcoming Investor Conferences
May 26, 2021
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
May 21, 2021
Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
Events

SEC Filings

Filing date Description Form View

Annual report which provides a comprehensive overview of the company for the past year

10-K View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA